CSF2 and influenza: Moreover, in a randomized, placebo-controlled trial, subcutaneous administration of GM-CSF, as a vaccine adjuvant, at the time of vaccination did not augment the antibody response to influenza or hepatitis A, or cellular response to tetanus and diphtheria toxoid in healthy volunteers (35,36).